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1. Introduction 
During pregnancy, a fetus can be affected by exposure to a variety of chemicals and 
pharmaceuticals. These effects can occur through exposure of the mother and subsequent 
placental transport. Thus, it is important to assess embryotoxicity (developmental toxicity 
without the observation of maternal toxicity) and teratogenicity (irreversible structure 
developmental effects without the observation of maternal adversities) prior to the 
marketing of compounds. The complexity of the reproductive system and the vast number 
of tissue targets for the exogenic induction of malformations during embryonic 
development are the rationale underlying the toxicity testing of chemicals in highly 
standardized animal experiments such as screening tests or multigenerational studies, 
according to specific Organization for Economic Co-operation and Development (OECD) 
test guidelines. All of these tests provide information on the biological effects of industrial 
chemicals or the pharmacological side effects. These guidelines generally specify time-
consuming and expensive in vivo experiments, most of which are performed with 
mammalian species such as rats or rabbits. However, for both economical and ethical 
reasons, there is a great demand for alternatives to living mammals in the testing of 
chemical-induced adverse effects on reproduction and development. Over the past 30 years, 
various in vitro models have been developed to detect the teratogenic effects of chemicals. 
These test systems utilize either dissociated cells from the limb buds and brains of rat 
embryos (micromass test; (Flint & Orton 1984)) or whole embryos of rats (whole embryo 
culture test; (Freeman & Steele 1986)). Thus, these test systems must sacrifice living animals 
in order to obtain cells or embryos for each experiment. In recent years, stem cells have 
become important new tools for the development of in vitro model systems to test drugs and 
chemicals; they have also shown potential to predict or estimate toxicity. Among various 
stem cells, embryonic stem (ES) cells are the most valuable in developing in vitro model 
systems because they are able to self-renew and differentiate into every cell type of the 
mammalian organism; they therefore have higher plasticity than adult stem cells. The fact 
that stem cells are able to self-renew means that they can be continuously cultured in an 
undifferentiated stage, giving rise to more specialized cells such as heart, liver, bone 
marrow, blood vessels, pancreatic islets, or neuronal cells upon addition or removal of 
certain growth factors (Hoffman & Merrill 2007). In 1997, Spielmann et al. developed an in 
vitro model for the screening of embryotoxicity based on mouse (m) ES cells. This is termed 
the “embryonic stem cell test” (EST; (Spielmann et al. 1997)). The EST is based on the 
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assessment of three toxicological endpoints: (1) the morphological analysis of beating 
cardiomyocytes in embryoid body (EB) outgrowths compared to cytotoxic effects on (2) 
undifferentiated mES cells, and (3) differentiated NIH-3T3 fibroblasts. As an in vitro system, 
which mirrors both proliferation and differentiation, the EST was proved in an international 
European Centre for the Validation of Alternative Methods (ECVAM) validation study to be 
a reliable assay for the prediction of embryotoxicity in vivo (Genschow et al. 2004). Using a set 
of 20 reference compounds with different embryotoxic potencies (nonembryotoxic, weakly 
embryotoxic, and strongly embryotoxic), the EST was demonstrated to provide a correct 
judgment in 78% of all experiments. Remarkably, a predictive performance of 100% was 
obtained for strong embryotoxicants. As a consequence, the validated EST has been accepted 
and successfully introduced by many pharmaceutical companies as a tool for testing the 
developmental toxicity of lead compounds at an early stage in the research and development 
of new drug candidates (Whitlow et al. 2007). A major drawback of the classical EST is its 
reliance on a morphological endpoint (beating cardiomyocytes) and the need for experienced 
personnel to ensure reliable assessments of this endpoint (Buesen et al. 2009).  
2. Technical details of EST 
2.1 Classical EST 
Murine ES cells are maintained in an undifferentiated state in culture under conditions that 
inhibit differentiation by supplementing the culture medium with murine leukemia 
inhibitory factor (mLIF; (Williams et al. 1988)). Differentiation of ES cells is then induced by 
the withdrawal of mLIF. Using the “hanging drop” culture technique described by Rudnicki 
and McBurney (Rudnicki & Mc Burney 1987), ES cells form multicellular aggregates called 
embryoid bodies (EBs; Fig. 1). Within the EBs, the three germ layers (endo-, meso-, and  
 
 
Fig. 1. Differentiation assay of the EST. ES cells are differentiated as EBs in hanging drops in 
differentiation medium. Differentiation medium containing 750 ES cells is placed on the lids of 
petri dishes filled with phosphate buffered saline (PBS) for 3 days. The EBs are transferred to 
suspension culture dishes and cultured for 2 days. They are plated onto 24-well tissue culture 
plates on day 5 and incubated for 5 additional days. To estimate the efficiency of 
differentiation from ES cells to cardiomyocytes, the distinctive beating movements of 
differentiated cardiomyocytes are analyzed under an inverted phase-contrast microscope. 
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ectoderm) can develop and the further differentiation into several cell types, including 
beating myocardial cells, can take place (Doetschman et al. 1985; Rudnicki & Mc Burney 
1987; Maltsev et al. 1994; Hescheler et al. 1997). The EST benefits from the fact that 
differentiation into beating myocardial cells can be easily detected by microscopic inspection 
of EB outgrowths at day 10 of differentiation. In addition to the differentiation analysis, the 
cytotoxic effects of the test substance on ES cells and NIH-3T3 cells are analyzed. By using 
stem cells and differentiated fibroblasts, the assay takes embryonic as well as maternal 
toxicity into account. To assess the concentration of a substance which inhibits the 
development (inhibition of differentiation: ID50) and proliferation (IC50ES and IC503T3) by 
50% compared to the untreated control, dose-response profiles are collected. A biostatistical 
prediction model was developed to assign test compounds to three classes of 
embryotoxicity: non-embryotoxic, weakly embryotoxic, and strongly embryotoxic (Genschow et 
al. 2002; Genschow et al. 2004).  
2.2 Modification of EST 
Arguments have been made that the classical, validated EST might be sufficient to assess the 
embryotoxic potential of chemicals (Marx-Stoelting et al. 2009). The differentiation of ES 
cells into cardiomyocytes is easy to achieve experimentally and is also highly reproducible. 
It has been reported that the spontaneous beating of cardiomyocytes represents a crucial 
first step during embryonic development. However, there is the possibility that the 
embryotoxic effects of chemicals might be overlooked if their underlying mechanisms of 
action consist of a very specific interaction with molecules that is expressed during the 
differentiation of ES cells into a cell type not well represented in the classical EST, such as a 
neuronal cell. It has also been argued that the EBs in the EST do not simply consist of 
beating cardiomyocytes, but also contain cells of other germ layers, including neuronal cells. 
Therefore, several suggestions have been made in regard to how to add further new 
endpoints (Buesen et al. 2004; Marx-Stoelting et al. 2009). These include additional ES cell 
differentiation endpoints, and the development of new molecular markers for the detection 
of toxic effects on embryonic development. One suggestion for the extension of endpoints 
was to differentiate ES cells into several different tissues, including nervous tissue, bone, 
cartilage, and epithelia. This approach would ensure that the effects on multilineage 
differentiation, and on tissue of endodermal, mesodermal, and ectodermal origin, would 
become detectable. It has been reported that the EC50 of thalidomide is ~30-fold lower when 
the effects were studied on the differentiation of ES cells triggered in the direction of bone 
tissue than in the classical EST with cardiac differentiation as the endpoint. Similarly, 
valproic acid (VPA) was more active (by a factor of ~10) in a regimen involving the 
induction of neuronal differentiation of ES cells (Marx-Stoelting et al. 2009). These results 
suggest that a multilineage analysis could increase the predictive performance of the EST. It 
is important to note that the observed differences in sensitivity correspond well with the 
two different developmental target tissues of thalidomide and VPA, which are primarily 
bone and the nervous system, respectively, but not the heart. Hence, the additional 
differentiation endpoints enabled the successful classification of the two agents, which was 
not possible with the classical EST (zur Nieden et al. 2004). This example not only 
demonstrates the relevance of additional differentiation endpoints, but also suggests that an 
increase in predictive value may be achievable using a combination of new differentiation 
endpoints with the introduction of new molecular markers (Marx-Stoelting et al. 2009). In 
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order to characterize the neural-tissue-specific toxicity of drugs, the stromal cell-derived 
inducing activity (SDIA) method, which promotes the differentiation of mES cells (Kawasaki 
et al. 2000; Kitajima et al. 2005), was introduced in the EST (Kusakawa et al. 2010) (Fig. 2). 
SDIA accumulates on the surface of PA6 stromal cells and induces efficient neuronal 
differentiation of cocultured ES cells in serum-free conditions without the use of either 
retinoic acid or EBs. A high proportion of tyrosine hydroxylase-positive neurons producing 
dopamine are obtained from SDIA-treated ES cells. (Kawasaki et al. 2000). This is one 
strategy for adding differentiation endpoints in the EST. 
 
Fig. 2. An in vitro neurotoxicity test established using a neural differentiation system 
induced by the stromal cell-derived inducing activity (SDIA) method. By performing 
various analyses of neural marker expressions, the effects of test drugs on the developing 
neural system can be evaluated. 
Several target genes and target proteins that could be used as molecular markers for the 
differentiation of specific embryonic tissues have been suggested and partially explored by 
methods employing quantitative real-time polymerase chain reaction (PCR) or fluorescence-
activated cell sorting (FACS) analysis (Seiler et al. 2004; Seiler et al. 2006; Buesen et al. 2009). 
In addition to the analysis of endogenous molecular markers, reporter-based systems may 
represent an attractive alternative. For example, mES cells that have been stably transfected 
with a neural-tissue-specific promoter-driven green fluorescence protein (GFP) or luciferase 
reporter can be utilized as a detection system. With this system, the effects on neural cell 
differentiation can be detected in a high-throughput assay based on GFP expression or 
luciferase activity (Kusakawa et al. 2010) (Fig. 3). Thus, reporter-based systems are regarded 
as promising, and may offer potential new endpoints for the EST (Marx-Stoelting et al. 
2009). 
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Fig. 3. Established ES cell lines that express reporter genes driven by each promoter of 
neuron marker gene, tubullin alpha 1 (Tα1), or glial cell marker gene, GFAP. In these stable 
cell lines, the expression of the reporter gene such as GFP (A) or luciferase (B) is observed, 
followed by neural differentiation. 
3. Actual case using modified EST 
3.1 Estimation of carbamazepine embryotoxicity using our modified EST 
Carbamazepine (CBZ) is one of the most widely used antiepileptic drugs (AEDs), and is also 
used in the treatment of neuropathic pains and psychiatric disorders (Albani et al. 1995; 
Sindrup & Jensen 1999). CBZ is known to be a teratogen (Jones et al. 1989; Shepard et al. 
2002). Pregnant women who undergo CBZ drug therapy have increased rates of congenital 
anomalies in the fetus, in particular, neural tube defects (NTDs), cardiovascular and urinary 
tract anomalies, and cleft palate. CBZ also induces a pattern of minor congenital anomalies 
and developmental retardation (Jones et al. 1989; Matalon et al. 2002). CBZ is structurally 
similar to tricyclic antidepressants, but shares remarkably similar clinical features to the 
structurally unrelated AED VPA, which has a short-chained fatty acid structure. CBZ is 
embryotoxic but is less teratogenic than VPA. It causes a spina bifida (an NTD) rate of 
approximately 0.5 to 1% and a cardiovascular anomaly rate of 1.5 to 2.0% (Ornoy 2006). VPA 
causes an NTD rate of approximately 2% and an increase of 4 to 8% in major congenital 
anomalies (Nau et al. 1991; Ornoy 2006). We attempted to characterize the tissue-specific 
embryotoxicity of CBZ using our modified EST (Murabe et al. 2007b).  
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Fig. 4. Analysis of expression levels for mesodermal and endodermal differentiation with CBZ. 
The expression level of markers of the undifferentiated state, Sox2 and Oct4 (A), endodermal 
markers, GATA6, TTR, HNF1, and ALB (B), and mesodermal markers, BMP4, Nkx2.5, and 
ANF (C-1), were quantified at each concentration of CBZ with real-time RT-PCR. The 
frequencies of cardiomyocytes, identified by their distinctive beating movements, derived 
from ES cells were quantified at each concentration of CBZ (C-2) (Murabe et al., 2007b). 
The tissue-specific effects of CBZ in the ES cell differentiation system were characterized at 
the molecular level. We used real-time reverse transcription (RT)-PCR on samples from day 
5 of culture to determine the expression levels of tissue-specific genes in undifferentiated 
cells, and in cells differentiating into endodermal and mesodermal lineages (Fig. 4). The 
expression levels of Sox2 and Oct4 (undifferentiated markers) increased at high CBZ 
concentrations (Fig. 4A). In the differentiating endodermal lineage, only the expression level 
of the primitive marker, GATA6, increased (Fig. 4B); the expression levels of the markers of 
late differentiation stages, TTR and HNF1, decreased in a concentration-dependent manner. 
Albumin (ALB), a definitive endodermal hepatic marker, was not detected, suggesting that 
CBZ promoted initial endodermal differentiation but inhibited differentiation into mature 
endodermal lineages. In the mesodermal lineage, the expression level of the primitive 
marker, BMP4, increased in a dose-dependent manner (Fig. 4C-1). The expression level of an 
early cardiac marker, Nkx2.5, showed a slight increase. However, expression of a later stage 
cardiac marker, ANF, was reduced in a concentration-dependent manner. Under the same 
culture conditions but omitting CBZ, cardiomyocytes normally differentiate from EBs. We 
screened for cardiomyocyte differentiation at different concentrations of CBZ. We found 
that CBZ decreased the rate of undifferentiated ES cells differentiating to cardiomyocytes in 
a dose-dependent manner (Fig. 4C-2). Thus, based on the gene expression data and rates of 
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cardiomyocyte differentiation, it is evident that CBZ promoted the initial differentiation into 
mesodermal lineages, including primitive cardiomyocytes, but inhibited later differentiation 
into the mature mesodermal lineages. We also examined the expression levels of various 
neural markers: Nestin, which is a marker of early differentiation, and Synaptophysin (Syn) 
and Neurofilament H (NFH), which are later stage neuron-specific markers. The expression 
of all three markers increased in a dose-dependent manner in the presence of CBZ (Fig. 5A-
1/2). The glial markers GFAP, an astrocyte-specific marker, and Oligo2 and DM20, 
oligodendrocyte-specific markers, were also elevated in a concentration-dependent manner 
(Fig. 5A-3). These results suggest that CBZ induces ES cells to differentiate into neurons and 
glial cells. This contrasts with our observation that VPA induces ES cells to differentiate into 
neurons but not glial cells (Murabe et al. 2007a). In order to compare the expression profiles 
of neuronal and glial markers between CBZ and VPA, we performed RT-PCR with samples 
on days 5 and 7. RT-PCR analysis revealed that the Nestin expression levels induced by CBZ 
were higher than those induced by VPA (Fig. 5B). Syn and NFH showed higher levels of 
expression after CBZ than VPA at day 5, but no expression of either marker could be 
detected at day 7 in the CBZ cultures. In contrast, the expression of Syn and NFH induced 
by VPA was increased in the day 7 culture. The DM20 expression levels in CBZ cultures 
were higher on days 5 and 7 than in the VPA cultures. The expression levels of other typical 
glial markers, such as GFAP, and Olig2, were very low (data not shown). Our 
immunocytochemical study with an antibody against β-III tubulin (a neuronal marker) 
 
 
Fig. 5. Analysis of expression levels for ectodermal differentiation with CBZ. (A) gene 
expression levels of the ectodermal markers, Nestin (1), Synaptophysin, NFH (2), and GFAP, 
Olig2, DM20 (3), were quantified by real-timeRT-PCR. (B) The expression levels of 
ectodermal markers were quantified by RT-PCR in cultures treated with CBZ (0.11 mM) or 
VAP (1.50 mM). (C) Neural cells derived from ES cells cultured in the presence of CBZ (0.05 
mM) or VPA (0.19 mM) were immunostained with an anti-βIII-tubulin antibody (Murabe et 
al., 2007b). 
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revealed that many positive cells were detected in samples on day 10 of cultures with either 
0.05 mM CBZ (Fig. 5C, left) or 0.19 mM VPA (Fig. 5C, right). In the CBZ-administered 
group, the positive cells had an almost spherical shape and few had nerve processes. These 
cells had the appearance of immature neurons. In contrast, in the VPA-administered group, 
many of the positive cells had long nerve processes and had the appearance of mature 
neurons. These results suggest that: (1) CBZ induces neural lineage differentiation in ES cells 
but that the potential for neuronal differentiation is lower compared with VPA; and (2) CBZ 
induces differentiation of both neuronal and glial lineages, whereas VPA induces neuronal 
but not glial cells.  
A cell viability assay was used to study the cytotoxic effect of CBZ on ES cells and NIH-3T3 
fibroblasts. In both cell lines, CBZ inhibited the survival of cells in a dose-dependent manner 
(Fig. 6). There was no significant difference between the cytotoxic sensitivities of ES cells 
and NIH-3T3 fibroblasts to CBZ. The IC50 values were calculated as 0.24 and 0.31 mM for 
NIH-3T3 fibroblasts and ES cells, respectively. The therapeutic range of CBZ is 0.02 to 0.05 
mM in serum. Thus, the IC50 values of NIH-3T3 fibroblasts and of ES cells were 
approximately 5- 15-fold larger than the therapeutic concentration. Neither cell line appears 
to show any significant response to CBZ within the therapeutic range. The cytotoxicity of 
CBZ for ES cells was much lower than that obtained for VPA in our system (Murabe et al. 
2007a). To observe the cytotoxic and morphological effects of CBZ, ES cells and NIH-3T3 
fibroblasts stained in MTT were observed on day 5 of the cytotoxicity assay (Fig. 6, bottom). 
In both cell types, cell densities were reduced in a concentration-dependent manner. In the 
high-dose CBZ group, NIH-3T3 fibroblasts showed strong indications of shrinkage or shape 
changes. In contrast, the ES cells contained many small, presumably undifferentiated cells, 
suggesting that CBZ strongly inhibited differentiation. This observation is almost the same 
as that found using VPA (Murabe et al. 2007a).  
 
 
Fig. 6. Cytotoxicity assay on ES cells and NIH-3T3 fibroblasts with CBZ. Cells on day 10 of 
the assay were stained with MTT and solubilized. The activity of the mitochondrial enzyme 
of living cells was examined. The violet color of the MTT formazan, which is the enzyme 
product, was measured at an absorbance of 520 nm. On day 5, cells were stained with MTT 
(Murabe et al., 2007b). 
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3.2 Estimation of fluoxetine embryotoxicity using our modified EST 
Twenty years have passed since fluoxetine, which is one of the selective serotonin-reuptake 
inhibitors (SSRIs), was introduced into clinical use; the class of antidepressants known as 
SSRIs is now used worldwide. Since their introduction, SSRIs have been recognized to be 
more effective and to have fewer side effects than older tricyclic antidepressants. For these 
reasons, treatment with SSRIs has become very popular, even among pregnant women, 
because approximately 10% of pregnant women exhibit symptoms of clinical depression 
and many are treated with antidepressants. Maternal use of SSRIs during pregnancy is of 
increasing public health concern, due to its wide prescriptive base for the treatment of 
depression and other disorders and its potential teratogenic effects on the developing fetus. 
Thus, we attempted to characterize the tissue-specific embryotoxicity of fluoxetine using our 
modified EST (Kusakawa et al. 2008). 
A cell viability assay was used to study the cytotoxic effect of fluoxetine on ES cells and 
NIH-3T3 fibroblasts. In both cell lines, fluoxetine inhibited survival of cells in a dose-
dependent manner (Fig. 7A and B), indicating that fluoxetine affected cell viability. The IC50 
values were calculated at 1.79 μM for ES cells and 4.67 μM for NIH-3T3 fibroblasts. There 
was a significant difference between these two cell lines in their cytotoxic sensitivities to 
fluoxetine, indicating that ES cells were more sensitive to the toxicity of fluoxetine than 
NIH-3T3 fibroblasts were.  
 
 
Fig. 7. Cytotoxicity assay on ES cells and NIH-3T3 fibroblasts with fluoxetine. (A) Cells on 
day 10 of the assay were stained with MTT and solubilized. The activity of the 
mitochondrial enzyme of living cells was examined. The violet color of the MTT formazan, 
which is the enzyme product, was measured at an absorbance of 520 nm. (B) On day 5, cells 
were stained with MTT (Kusakawa et al. 2008). 
To characterize the tissue-specific effects of fluoxetine on the ES differentiation system at the 
molecular level, we examined the expression levels of typical tissue-specific genes by 
performing real-time RT-PCR analysis on our samples on days 5 and 10 of the 
differentiation assay (Figs. 8– 10). Under a control culture condition without the drug (0 μM 
fluoxetine), the undifferentiated markers Oct3/4 and Sox2 were highly expressed on day 5, 
and their expression levels decreased between day 5 and day 10. In fluoxetine-treated ES  
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Fig. 8. Analysis of expression levels for the differentiated state and endodermal 
differentiation. The expression levels of the undifferentiated markers, sox2 and Oct3/4 (A), 
and endoderm markers, GATA6, TTR, AFP, and ALB (B), were quantified at each 
concentration of fluoxetine (0 μM: open circle; 1μM: closed triangle; 3μM: closed square) 
with real-time RT-PCR (Kusakawa et al. 2008). 
cells, on the other hand, the expression levels of Oct3/4 and Sox2 were lower on day 5, but 
increased between day 5 and day 10 (Fig. 8A). There were significant interactions between 
fluoxetine treatment and the expression pattern of each undifferentiated marker. These results 
suggested that fluoxetine treatment affected the expression of the undifferentiated markers 
Oct3/4 and Sox2 in differentiating ES cells. Under the control culture condition, the expression 
levels of endodermal markers such as GATA6, TTR, AFP, and albumin (ALB) were low on day 
5 and up-regulated from day 5 to day 10 (Fig. 8B). In fluoxetine-treated ES cells, in contrast, 
these endodermal markers were more strongly expressed on day 5, and down-regulated from 
day 5 to day 10. There were significant interactions between fluoxetine treatment and the 
expression pattern of each endodermal marker, suggesting that fluoxetine could also affect the 
differentiating endodermal lineage. The expression levels of BMP4 (a primitive marker), 
Nkx2.5 (an early cardiac marker), MLC-2v, and ANF (both later cardiac markers) were low on 
day 5 and increased between day 5 and day 10 under the control culture condition (Fig. 9A). In 
the fluoxetine-treated cells, on the other hand, these mesodermal markers were more highly 
expressed on day 5, and decreased between day 5 and day 10 (Fig. 9A). There were significant 
interactions between fluoxetine treatment and the expression pattern of each endodermal 
marker. Thus, fluoxetine treatment down-regulated the expressions of mesodermal markers as 
well as endodermal markers. In addition to studying gene expression levels in the mesodermal 
lineages, we examined how fluoxetine affected mesodermal cell differentiation. Ordinarily, in 
the absence of fluoxetine, cardiomyocyte can differentiate from EBs at different concentrations  
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Fig. 9. Analysis of expression levels for mesodermal differentiation. The expression levels of 
the mesodermal markers, BMP4, Nkx2.5, MLC-2v, and ANF were quantified at each 
concentration of fluoxetine (0 μM: open circle; 1 μM: closed triangle; 3 μM: closed square) 
with real-time RT-PCR (A). The frequencies of cardiomyocytes derived from ES cells were 
identified by their distinctive beating movement and quantified at each concentration of 
fluoxetine (B) (Kusakawa et al. 2008). 
of fluoxetine. We found that fluoxetine decreased the rate at which undifferentiated ES cells 
differentiated to cardiomyocytes in a concentration-dependent manner (Fig. 9B). The ID50 
value was calculated at 3.79 μM. Thus, based on the gene expression data and the 
cardiomyocyte differentiation data, it was confirmed that fluoxetine could inhibit 
differentiation into mesodermal lineages.  
In the absence of fluoxetine, the expression level of Nestin (a primitive neural stem cell 
marker) was low on day 5, and increased slightly on day 10. In fluoxetine-treated cells, in 
contrast, the expression level of Nestin was higher on day 5 and decreased between day 5 
and day 10. Similarly, the expression levels of synaptophysin (a later neuron-specific 
marker), GFAP (an astrocyte-specific marker), and Olig2 (an oligodendrocyte-specific 
marker) in fluoxetine-treated cells were lower on day 5 and increased from day 5 to day 10 
(Fig. 10A). There were significant interactions between fluoxetine treatment and the 
expression pattern of each ectodermal marker. The expression levels of GFAP and Olig2 
increased in a concentration-dependent manner (GFAP: 3-fold increase at 1 μM and 18-fold 
increase at 3 μM; Olig2: 2-fold increase at 1 μM and 20-fold increase at 3 μM). We also 
performed an immunocytochemical study with antibodies against Neurofilament H (NFH) 
(a later neuron-specific marker) and GFAP (an astrocyte-specific marker). Among ES cells 
that had been treated with 3 μM fluoxetine, we detected many positive cells, both for NFH 
and for GFAP, on day 10 (Fig. 10B). In this fluoxetine-treated group, the positive cells had an 
almost spherical shape, and few had any nerve processes (Fig. 10B). These cells had the 
appearance of immature neurons. These results suggest that fluoxetine induces ectodermal 
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lineage differentiation in ES cells, but that the potential for neuronal differentiation is lower 
compared with that for glial lineages.  
 
 
Fig. 10. Analysis of expression levels for ectodermal differentiation. The expression levels of 
the ectodermal markers, Nestin, Synaptophysin, GFAP, and Olig2 were quantified at each 
concentration of fluoxetine (0 μM: open circle; 1 μM: closed triangle; 3 μM: closed square) 
with real-time RT-PCR (A). Neural and glial cells derived from ES cells were cultured in the 
presence of fluoxetine (3 μM) and immunostained with NFH antibody and GFAP antibody 
(B) (Kusakawa et al. 2008). 
4. Further improvement for EST 
The issue of the necessity of adding a metabolic system to the EST to ensure the metabolic 
activation of potential embryotoxicants has been actively discussed (Marx-Stoelting et al. 
2009). Potential experimental procedures are the use of cultured hepatocytes, especially 
human primary hepatocytes. Hepatocytes may be useful in systems when a preincubation 
step is applied to a chemical or a pharmaceutical and subsequently added to the ES cell 
culture with the active metabolite. Whether or not the development of a metabolic activation 
system for the EST is truly required has been the subject of much discussion, given the 
difficulties associated with it (Marx-Stoelting et al. 2009). Many hepatotoxicities arise from 
metabolites derived from drugs (Park et al. 2005). For this reason, it is important to use an 
assay system with cells that harbor drug-metabolizing enzymes to assess the drug toxicity 
accurately. In addition, maternal metabolism and fetoplacental interaction have to be taken 
into account, because some proteratogens require bioactivation to provide the active 
molecule (Brown et al. 1986). Therefore, the inclusion of a reliable metabolizing system 
would extend the usefulness of in vitro test procedures. 
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Among the various toxic tests, an EST can determine embryotoxicity and teratogenicity, and 
it does not require experimental animals. The EST has thus far been modified by being 
combined with real-time PCR, FACS analysis, GFP reporter analysis, or luciferase reporter 
analysis to detect molecular markers as new endpoints for the EST. In addition, some 
methods for ES cell differentiation into several cell types such as neural cells have been 
attempted to identify additional differentiation endpoints. However, further improvement 
of the EST is needed in order to investigate the harmful effects of chemicals and 
pharmaceuticals more exhaustively. For instance, a metabolic system designed to detect 
proteratogenic compounds has to be integrated in order to extend the applicability. 
Furthermore, a main advantage of embryotoxicity testing by the EST is the availability of 
human ES cells. Not all mammalian species are equally susceptible or sensitive to the toxic 
influences of a chemical. A compound that brings out defects in one species can have other 
or no effects on another species. Using two or more species for regulatory developmental 
toxicity testing currently covers the detection of genetic differences that influence the 
response to a chemical. A test system based on mES cells can now be adapted to human ES 
cells. The use of a humanized test system will have much greater predictive ability because 
some developmental pathways that could act as targets for chemicals are specific to human 
development. Thus, the EST can be significantly improved by combining tissue 
differentiation systems and/or metabolic systems, or by using human ES cells in the quick 
and accurate estimation of the in vivo embryotoxic effects of various medicines. 
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